A phase 1/2 study of kamuvudines - Inflammasome Therapeutics for the treatment of Geographic Atrophy (GA), the most severe form of dry AMD
Latest Information Update: 15 Nov 2023
At a glance
- Drugs Kamuvudine 8 (Primary)
- Indications Dry macular degeneration
- Focus Adverse reactions
- 13 Nov 2023 According to an Inflammasome Therapeutics media release, the FDA has granted approval for the opening of this study
- 13 Dec 2021 New trial record
- 06 Dec 2021 According to an Inflammasome Therapeutics media release, this trial is expected to begin in 2022.